Oppenheimer upgrades Teva, despite legal uncertainty, with stock at 19-year low
Oppenheimer analyst Esther Rajavelu upgraded Teva Pharmaceutical to Outperform from Perform while lowering her price target for the shares to $12 from $17. The stock closed Friday down 19c to $8.65. The shares, trading at its 19-year low, offer a buying opportunity, Rajavelu tells investors in a research note. The analyst believes Teva's business fundamentals continue to improve and that management's execution on the operational front is generally in line with expectations. She acknowledges, however, that legal uncertainties could remain an overhang the stock. Rajavelu estimates the company's opioid liability exposure at $500M-$700M and believes its price-fixing exposure could be "substantially higher." Teva's balance sheet, assuming the refinancing of certain debt tranches, could sustain $400M in average annual penalties over time, says the analyst.